To blind or not to blind first in human and exploratory clinical trials: Acceleration of development vs. risk of bias

An IQ consortium working group (WG) conducted a survey across multiple biopharmaceutical companies to gain information about the level of blinding commonly utilized for early clinical development trials. The main objectives were: (1) to understand blinding practices between healthy volunteer (HV) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Haertter, Sebastian, Kanodia, Jitendar, Cook, Jack, Alicea, Jeanette, Brennan, Bonnie J., Desai, Amit, Patel, Bela, Pan, Lin, Goteti, Kosalaram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932719/
https://www.ncbi.nlm.nih.gov/pubmed/34786861
http://dx.doi.org/10.1111/cts.13200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932719/
https://www.ncbi.nlm.nih.gov/pubmed/34786861
http://dx.doi.org/10.1111/cts.13200

Ejemplares similares